BSE - Delayed Quote INR

Concord Drugs Limited (CONCORD.BO)

31.80
-0.87
(-2.66%)
At close: June 6 at 3:27:16 PM GMT+5:30
Loading Chart for CONCORD.BO
  • Previous Close 32.67
  • Open 32.60
  • Bid 31.55 x --
  • Ask 32.00 x --
  • Day's Range 31.25 - 33.29
  • 52 Week Range 26.10 - 41.00
  • Volume 3,097
  • Avg. Volume 7,071
  • Market Cap (intraday) 318M
  • Beta (5Y Monthly) 0.20
  • PE Ratio (TTM) 93.53
  • EPS (TTM) 0.34
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products. The company also provides ready-to-fill pellets and multiple unit pellets system; drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. Concord Drugs Limited was incorporated in 1995 and is based in Hyderabad, India.

concorddrugs.in

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: CONCORD.BO

View More

Performance Overview: CONCORD.BO

Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

CONCORD.BO
15.65%
S&P BSE SENSEX (^BSESN)
5.18%

1-Year Return

CONCORD.BO
12.44%
S&P BSE SENSEX (^BSESN)
9.48%

3-Year Return

CONCORD.BO
12.44%
S&P BSE SENSEX (^BSESN)
47.62%

5-Year Return

CONCORD.BO
12.44%
S&P BSE SENSEX (^BSESN)
139.71%

Compare To: CONCORD.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CONCORD.BO

View More

Valuation Measures

Annual
As of 6/6/2025
  • Market Cap

    318.00M

  • Enterprise Value

    486.46M

  • Trailing P/E

    93.53

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.69

  • Price/Book (mrq)

    0.93

  • Enterprise Value/Revenue

    1.08

  • Enterprise Value/EBITDA

    11.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.74%

  • Return on Assets (ttm)

    2.73%

  • Return on Equity (ttm)

    0.99%

  • Revenue (ttm)

    452.45M

  • Net Income Avi to Common (ttm)

    3.36M

  • Diluted EPS (ttm)

    0.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.25M

  • Total Debt/Equity (mrq)

    56.41%

  • Levered Free Cash Flow (ttm)

    72.16M

Research Analysis: CONCORD.BO

View More

Company Insights: CONCORD.BO

Research Reports: CONCORD.BO

View More

People Also Watch